Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Still A COVID-19 Game Changer? UK’s Cautious Launch Of MSD’s Antiviral Lagevrio

Efficacy In Vaccinated Population Unproven

Executive Summary

The oral therapy is likely to be a useful addition to the COVID-19 armamentarium, but hopes of it being a ‘game changer’ now look overly optimistic.

You may also be interested in...



Pharma’s Voluntary Licensing In India Successful In 2021 – But There Were Some Delicate Moments

Merck and Lilly tackle some early challenges before striking voluntary licensing deals for COVID-19 therapies with Indian firms. Data around the use of these drugs in low- and middle-income countries could also potentially make them ‘more acceptable’ elsewhere, experts say.

Pfizer Confirms Paxlovid’s High Efficacy And Reassures On Omicron

While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.

The BioPharma Shares Rising On Omicron Hopes And Fears

Adagio Therapeutics and Gritstone bio are two companies who could add to the armamentarium against Omicron.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel